|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Table A2: Patient Baseline Characteristics, Matched, Favorable Risk, Black men vs White men** | | | | | |
|  |  | Black | White | P-value | SMD |
|  |  | 3724 | 3724 |  |  |
|  |  |  |  |  |  |
| Treatment | BT | 564 (15.1) | 563 (15.1) | 0.584 | 0.032 |
|  | EBRT alone | 555 (14.9) | 565 (15.2) |  |  |
|  | RP alone | 1367 (36.7) | 1411 (37.9) |  |  |
|  | RP and PLND | 1238 (33.2) | 1185 (31.8) |  |  |
| Facility type | Community Cancer Program | 225 (6.0) | 214 (5.7) | 0.929 | 0.022 |
|  | Comprehensive Community Cancer Program | 1454 (39.0) | 1459 (39.2) |  |  |
|  | Academic/Research Program | 1566 (42.1) | 1550 (41.6) |  |  |
|  | Integrated Network Cancer Program | 473 (12.7) | 495 (13.3) |  |  |
|  | unknown | 6 (0.2) | 6 (0.2) |  |  |
| geography | New England | 136 (3.7) | 143 (3.8) | 0.619 | 0.062 |
|  | Middle Atlantic | 574 (15.4) | 568 (15.3) |  |  |
|  | South Atlantic | 1326 (35.6) | 1243 (33.4) |  |  |
|  | East North Central | 581 (15.6) | 627 (16.8) |  |  |
|  | East South Central | 429 (11.5) | 451 (12.1) |  |  |
|  | West North Central | 155 (4.2) | 138 (3.7) |  |  |
|  | West South Central | 217 (5.8) | 233 (6.3) |  |  |
|  | Mountain | 37 (1.0) | 41 (1.1) |  |  |
|  | Pacific | 263 (7.1) | 274 (7.4) |  |  |
|  | unknown | 6 (0.2) | 6 (0.2) |  |  |
| insurance | No insurance | 57 (1.5) | 63 (1.7) | 0.579 | 0.045 |
|  | Private Insurance | 2236 (60.0) | 2161 (58.0) |  |  |
|  | Medicaid | 77 (2.1) | 77 (2.1) |  |  |
|  | Medicare | 1245 (33.4) | 1311 (35.2) |  |  |
|  | Other Government | 72 (1.9) | 69 (1.9) |  |  |
|  | unknown | 37 (1.0) | 43 (1.2) |  |  |
| income | $38,000 - $47,999 | 921 (24.7) | 1016 (27.3) | 0.125 | 0.062 |
|  | $48,000 - $62,999 | 962 (25.8) | 925 (24.8) |  |  |
|  | $63,000 + | 1065 (28.6) | 1013 (27.2) |  |  |
|  | < $38,000 | 768 (20.6) | 759 (20.4) |  |  |
|  | unknown | 8 (0.2) | 11 (0.3) |  |  |
| charleson deyo comorbidity index | 0 | 3109 (83.5) | 3044 (81.7) | 0.137 | 0.046 |
|  | 1 | 537 (14.4) | 592 (15.9) |  |  |
|  | 2+ | 78 (2.1) | 88 (2.4) |  |  |
| Age, mean (SD), years |  | 61.46 (7.74) | 61.77 (7.90) | 0.081 | 0.04 |
| risk | favorable intermediate | 1558 (41.8) | 1640 (44.0) | 0.058 | 0.044 |
|  | Low | 2166 (58.2) | 2084 (56.0) |  |  |
| Diagnosis to treatment initiation time | 0-90 | 2021 (54.3) | 1977 (53.1) | 0.202 | 0.041 |
|  | >90 | 1428 (38.3) | 1432 (38.5) |  |  |
|  | unknown | 275 (7.4) | 315 (8.5) |  |  |
| clinical T stage | T1 | 3087 (82.9) | 3029 (81.3) | 0.085 | 0.041 |
|  | T2 | 637 (17.1) | 695 (18.7) |  |  |
| clinical Gleason score | <=6 | 2319 (62.3) | 2256 (60.6) | 0.14 | 0.035 |
|  | 7 | 1405 (37.7) | 1468 (39.4) |  |  |
| PSA | <10 | 3552 (95.4) | 3533 (94.9) | 0.333 | 0.024 |
|  | 10-20 | 172 (4.6) | 191 (5.1) |  |  |
| *Abbreviations: BT=brachytherapy; EBRT=external beam radiotherapy; RP=Radical Prostatectomy; PLND=pelvic lymph node dissection; SMD=Standardized mean difference; CI=Confidence Interval; fIR=favorable intermediate risk; LR=low risk; AfA=African American; Cc=Caucasian* | | | | | |
| \*ng/ml | | | | | |
| \*\*combined gleason score | | | | | |